What is the current valuation of the UK drug repurposing market?

The market valuation was $15.0 Million in 2024. Read More

What is the projected market size for the UK drug repurposing market by 2035?

The projected valuation for 2035 is $70.0 Million. Read More

What is the expected CAGR for the UK drug repurposing market during 2025 - 2035?

The expected CAGR is 15.03% during the forecast period. Read More

Which companies are the key players in the UK drug repurposing market?

Key players include Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc, and Amgen Inc. Read More

What are the main segments of the UK drug repurposing market?

The main segments include Type, Therapeutic Area, and Drug Molecules. Read More

How did the Disease-centric segment perform in 2024?

The Disease-centric segment was valued at $5.0 Million in 2024. Read More

What is the valuation of the Small Molecule segment in the UK drug repurposing market?

The Small Molecule segment is valued at $10.0 Million. Read More

What is the valuation range for the Different Therapeutic Area segment?

The Different Therapeutic Area segment ranges from $4.5 Million to $21.5 Million. Read More

How does the valuation of Biologics compare to Small Molecules in 2024?

Biologics were valued at $5.0 Million, while Small Molecules were valued at $10.0 Million. Read More

What is the expected growth trend for the UK drug repurposing market?

The market is likely to experience substantial growth, reaching $70.0 Million by 2035. Read More

UK Drug Repurposing Market

ID: MRFR/Pharma/50631-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

UK Drug Repurposing Market Research Report: Size, Share, Trend Analysis By Typess (Disease-centric, Target-centric, Drug-centric), By Therapeutic Area (Same Therapeutic Area, Different Therapeutic Area) and By Drug Molecules (Biologics, Small Molecule) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
  1. 4.1.1 Disease-centric
  2. 4.1.2 Target-centric
  3. 4.1.3 Drug-centric
2. 4.2 Industrial Automation & Equipment, BY Therapeutic Area (USD Million)
  1. 4.2.1 Same Therapeutic Area
  2. 4.2.2 Different Therapeutic Area
3. 4.3 Industrial Automation & Equipment, BY Drug Molecules (USD Million)
  1. 4.3.1 Biologics
  2. 4.3.2 Small Molecule
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis AG (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca PLC (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Eli Lilly and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Gilead Sciences Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen Inc (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY TYPE
3. 6.3 UK MARKET ANALYSIS BY THERAPEUTIC AREA
4. 6.4 UK MARKET ANALYSIS BY DRUG MOLECULES
5. 6.5 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
8. 6.8 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC AREA, 2024 (% SHARE)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG MOLECULES, 2024 (% SHARE)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG MOLECULES, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
  3. 7.2.3 BY DRUG MOLECULES, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Type (USD Million, 2025-2035)

Disease-centric
Target-centric
Drug-centric

Industrial Automation & Equipment By Therapeutic Area (USD Million, 2025-2035)

Same Therapeutic Area
Different Therapeutic Area

Industrial Automation & Equipment By Drug Molecules (USD Million, 2025-2035)

Biologics
Small Molecule

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”